Transplantation · 2005 · 109 citations · 13 references
Life SciencesImmunologyPharmacologyImmunotherapyKidney TransplantationTransplant ImmunologyAcute RejectionGraft RejectionImmunosuppression In Kidney TransplantationRejection ProphylaxisTransplant PharmacologyTransplant RejectionAlemtuzumab UseAlemtuzumab-based ConditioningKidney Transplant ImmunosuppressionRenal Transplant RejectionSerum Creatinine AssessmentT Cell-mediated Graft RejectionTransplantationTreatment Of Rejection Episodes
BACKGROUND: A randomized, multicenter, controlled trial was undertaken to evaluate the safety and efficacy of Alemtuzumab, a powerful lytic agent for both T and B lymphocytes, in the prophylaxis of rejection in renal transplantation (RTx). METHODS: Thirty patients were randomized to receive Alemtuzumab together with low-dose cyclosporine (CsA) monotherapy (CAMPATH, n = 20) or to full doses of CsA with azathioprine and corticosteroids (Standard, n = 10). CsA was administered at doses to achieve whole-blood trough CsA levels of 90 to 110 ng/mL and 180 to 225 ng/mL in CAMPATH and Standard groups, respectively. RESULTS: Per protocol, CsA trough levels were lower in patients assigned to CAMPATH post-RTx (median trough level of 119 vs. 166 ng/mL at 6 months, CAMPATH vs. Standard; 95% confidence interval, -92 to -34). At 6 months post-RTx, serum creatinine, graft and patient survivals, incidence of biopsy proven acute rejection (25% vs. 20%, CAMPATH vs. Standard), overall treatment failure, and severe and moderate infections were comparable. Whereas all patients receiving Standard therapy required maintenance corticosteroids at 6 months, of the 17 of 20 patients with functioning grafts in CAMPATH, 15 (88%, 95% confidence interval, 53%-97%) were steroid free. CONCLUSION: These results suggest that Alemtuzumab is an effective induction agent that permits low-dose steroid-free immunosuppression in RTx.
13
REMISSION INDUCTION IN NON-HODGKIN LYMPHOMA WITH RESHAPED HUMAN MONOCLONAL ANTIBODY CAMPATH-1H
G Hale, Mike Clark, R. Marcus et al. · The Lancet · 1988 · 692 citations
G Hale, Meng‐Q. Xia, Helen Tighe et al. · Tissue Antigens · 1990 · 329 citations